A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

RecruitingOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
NSCLC, Non-small-cell Lung Carcinoma
Trial Locations (24)

Unknown

RECRUITING

Research Site, Arkhangelsk

RECRUITING

Research Site, Chelyabinsk

RECRUITING

Research Site, Grozny

RECRUITING

Research Site, Irkutsk

NOT_YET_RECRUITING

Research Site, Kemerovo

RECRUITING

Research Site, Khanty-Mansiysk

RECRUITING

Research Site, Kostroma

NOT_YET_RECRUITING

Research Site, Krasnodar

RECRUITING

Research Site, Krasnoyarsk

RECRUITING

Research Site, Moscow

RECRUITING

Research Site, Murmansk

RECRUITING

Research Site, N.Novgorod

RECRUITING

Research Site, Novosibirsk

RECRUITING

Research Site, Perm

RECRUITING

Research Site, Saint Petersburg

RECRUITING

Research Site, Sochi

RECRUITING

Research Site, Surgut

NOT_YET_RECRUITING

Research Site, Syktyvkar

RECRUITING

Research Site, Tomsk

RECRUITING

Research Site, Ufa

RECRUITING

Research Site, Vologda

RECRUITING

Research Site, Yaroslavl

RECRUITING

Research Site, Yekaterinburg

RECRUITING

Research Site, Yuzhno-Sakhalinsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY